Skip to main content

Cutaneous T-cell lymphoma

EDM (Early Day Motion) 1347: tabled on 12 January 2021

Tabled in the 2019-21 session.

This motion has been signed by 18 Members. It has not yet had any amendments submitted.

Motion text

That this House notes the rare blood cancer, Cutaneous T-cell lymphoma (CTCL) is a serious and potentially life-threatening cancer that affects the skin, blood, lymph nodes and internal organs; recognizes that people living with the disease have a substantially reduced quality of life; highlights that living with a diagnosis of mycosis fungoides or Sézary syndrome, two subtypes of CTCL, is challenging, both from a symptoms management and psycho-social point of view; emphasizes the poor prognosis for people diagnosed with an advanced stage of the condition; and calls for greater awareness of this disease and more equitable access to treatment and care for those living with this rare, debilitating haematological malignancy.

The first 6 Members who have signed to support the motion are the sponsors. The primary sponsor is generally the person who tabled the motion and has responsibility for it. The date shown is when the Member signed the motion.

In addition to the sponsors, the following Members have signed to support the motion.

There are no withdrawn signatures for this motion.